Latest Conference Articles

Dr. Mato on the Benefits of the JTCC Retrospective Trial

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

Photos From the 2011 ASH Annual Meeting and Exposition

A collection of photos from the ASH 53rd annual meeting at the San Diego Convention Center in San Diego, CA, from December 10-13, 2011.

Ponatinib Continues March to Potential Front-line Use in CML

PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation

Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions

Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101

Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia

Adding gemtuzumab to chemotherapy improved event-free and OS of newly diagnosed patients with acute myeloid leukemia.

Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)

Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).

Dr. Kochenderfer Discusses the B-cell Antigen CD19

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

Dr. Feldman Discusses the Difficulties of Rare Lymphomas

Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas

Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.

Photos From the 2011 San Antonio Breast Cancer Symposium

A collection of photos from the 34th annual SABCS at the Henry B. Gonzalez Convention Center in San Antonio, TX, from December 6-10, 2011.

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial

Dr. José Baselga from Massachusetts General Hospital Discusses the CLEOPATRA Pertuzumab Trial

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

Dr. Tripathy on the AVEREL Bevacizumab Trial Results

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial

The CLEOPATRA and BOLERO-2 Studies are Stirring Excitement at SABCS

The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.

Dr. Smith on the Brachytherapy Breast Cancer Trial

Dr. Benjamin Smith from MD Anderson Cancer Center Discusses the Brachytherapy Breast Cancer Trial

New Test Predicts Recurrence Risk in Patients With Ductal Carcinoma in Situ

A new 12-gene assay for predicting risk of recurrence for patients with ductal carcinoma in situ (DCIS).

Dr. Solin Discusses the DCIS Score Recurrence Test

Dr. Lawrence Solin from Einstein Medical Center Discusses the DCIS Score Recurrence Test

Gene Signature Identifies Early Versus Late Versus No Recurrence in Hormone Receptor-Positive Breast Cancer

It may be possible to predict which women with HR+ invasive breast cancer will experience recurrence by using a series of gene expression profiles.